Otsuka Holdings Co., Ltd.

The US Food and Drug Administration has a new message for industry representatives on advisory committees: You can be here, but don’t talk too much. Nonvoting representatives, including the industry r

Scrip regularly covers business development and deal making in the biopharmaceutical industry. Asia Deal Watch is supported by deal intelligence from Biomedtracker. Taiho Sends Benz LSD1 Inhibitor Fo

Otsuka’s release of supplemental Phase III data on June 6 for sibeprenlimab was the second major data readout in immunoglobulin A nephropathy (IgAN) of the week, following Vera’s Phase III data on Jun

Although Novartis’s immunoglobulin A nephropathy (IgAN) franchise will face considerable competition from other firms, the accelerated approval in the US of Vanrafia (atrasentan) further solidifies it